James Garner CEO upbeat on prospects., page-2

Novogen Appoints Dr James Garner as Chief Executive OfficerNEWS PROVIDED BYNovogen Ltd 09 Dec, 2015, 04:59 ETSYDNEY, Dec. 9, 2015 /PRNewswire/ -- US-Australian drug discovery company, Novogen Limited (ASX:NRT;

NASDAQ:NVGN) today announced the appointment of Dr James Garner as Chief Executive Officer. Dr Garner will take up the role on 1 February 2016, at which time he will be appointed to the Board of Directors of Novogen.Dr Garner, 42, brings broad experience in drug development and commercialisation, acquired through regional and global roles in the biotech and pharmaceutical sector. His previous responsibilities have included leading non-clinical safety and efficacy, phase I-IV clinical trials, product registration, reimbursement, medical marketing and business development.
Dr Garner is currently Head of the Unit Development Office, AP R&D with Sanofi and is based in Singapore. He will relocate to Sydney in the New Year.After qualifying in medicine at Imperial College in London, Dr Garner spent several years as a practicing clinician in the UK and Australia before joining Bain & Company, a global management consulting company in 2002. He subsequently worked with Biogen and Progen Pharmaceuticals in Australia and with Quintiles, an international clinical research organisation in Singapore.In 2009, he was appointed Regional Vice President for Takeda Pharmaceutical Company with overall responsibility for all clinical development activities and registration of new chemical entities in the Asian region (excluding Japan), and served as General Manager of the company's regional R&D Hub in Singapore.
In mid-2013, Dr Garner took up his current role at Sanofi. Aside from his medical qualifications, Dr Garner holds a BSc (with First Class Honours) from University College London, an MA in Philosophy and an MBA from the University of Queensland, and a postgraduate qualification in Applied Finance & Investment from the Financial Services Institute of Australasia. In 2008, he was named a 'Young Executive of the Year' by the Australian Financial Review's BOSS Magazine.In announcing the appointment, Novogen's Interim Chairman, Ian Phillips welcomed Dr Garner to the Company. "James is joining Novogen at an exciting time and he brings a wealth of relevant experience from the international pharmaceutical and biotech sector. I am confident as CEO, he will lead us through the next stage of the Company's development and achieve both our short and long term goals," Mr Phillips said.